Paper39733394
Synergistic effects of dihydroartemisinin and cisplatin on inducing ferroptosis in gastric cancer through GPX4 inhibition.
Wang H and 7 others. Gastric Cancer, 2025. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Synergistic effects of dihydroartemisinin and cisplatin on inducing ferroptosis in gastric cancer through GPX4 inhibition. Papers, record 39733394. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39733394
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Synergistic effects of dihydroartemisinin and cisplatin on inducing ferroptosis in gastric cancer through GPX4 inhibition.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ferroptosis | Major topic |
| Cisplatin | Major topic |
| Artemisinins | Major topic |
| Stomach Neoplasms | Major topic |
| Phospholipid Hydroperoxide Glutathione Peroxidase | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Drug Synergism | |
| Mice | |
| Animals | |
| Cell Proliferation | |
| Xenograft Model Antitumor Assays | |
| Cell Line, Tumor | |
| Mice, Nude | |
| Mice, Inbred BALB C | |
| Tumor Cells, Cultured |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| BE20201230 | Natural Science Foundation of Jiangsu Province | PubMed |
Source PubMed
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35782905 | Effects of dihydroartemisinin combined with cisplatin on proliferation, apoptosis and migration of HepG2 cells. | Oncol Lett | 2022 | https://conductscience.org/library/papers/35782905 | PubMed |
| 2 | 29394020 | Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions. | Met Ions Life Sci | 2018 | https://conductscience.org/library/papers/29394020 | PubMed |
| 3 | 17549417 | Selected flavonoids potentiate the toxicity of cisplatin in human lung adenocarcinoma cells: a role for glutathione depletion. | Int J Oncol | 2007 | https://conductscience.org/library/papers/17549417 | PubMed |
| 4 | 37182516 | Medicinal and mechanistic overview of artemisinin in the treatment of human diseases. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37182516 | PubMed |
| 5 | 33613116 | Dihydroartemisinin: A Potential Natural Anticancer Drug. | Int J Biol Sci | 2021 | https://conductscience.org/library/papers/33613116 | PubMed |
| 6 | 37399587 | SLC7A11 promotes the progression of gastric cancer and regulates ferroptosis through PI3K/AKT pathway. | Pathol Res Pract | 2023 | https://conductscience.org/library/papers/37399587 | PubMed |
| 7 | 30896757 | Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/30896757 | PubMed |
| 8 | 8385085 | Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. | Jpn J Cancer Res | 1993 | https://conductscience.org/library/papers/8385085 | PubMed |
| 9 | 26794443 | Ferroptosis: process and function. | Cell Death Differ | 2016 | https://conductscience.org/library/papers/26794443 | PubMed |
| 10 | 35143424 | Cancer statistics in China and United States, 2022: profiles, trends, and determinants. | Chin Med J (Engl) | 2022 | https://conductscience.org/library/papers/35143424 | PubMed |
| 11 | 31680182 | Dihydroartemisinin and its anticancer activity against endometrial carcinoma and cervical cancer: involvement of apoptosis, autophagy and transferrin receptor. | Singapore Med J | 2021 | https://conductscience.org/library/papers/31680182 | PubMed |
| 12 | 28078787 | Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress. | Fundam Clin Pharmacol | 2017 | https://conductscience.org/library/papers/28078787 | PubMed |
| 13 | 37069625 | Artemisinin derivatives induce oxidative stress leading to DNA damage and caspase-mediated apoptosis in Theileria annulata-transformed cells. | Cell Commun Signal | 2023 | https://conductscience.org/library/papers/37069625 | PubMed |
| 14 | 36928207 | Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein. | Cell Death Discov | 2023 | https://conductscience.org/library/papers/36928207 | PubMed |
| 15 | 36721820 | Ferroptosis as a Potential Cell Death Mechanism Against Cisplatin-Resistant Lung Cancer Cell Line. | Adv Pharm Bull | 2023 | https://conductscience.org/library/papers/36721820 | PubMed |
| 16 | 36068393 | Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma. | J Nat Med | 2023 | https://conductscience.org/library/papers/36068393 | PubMed |
| 17 | 35163459 | Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163459 | PubMed |
| 18 | 37605406 | Anticancer Effect of Dihydroartemisinin via Dual Control of ROS-induced Apoptosis and Protective Autophagy in Prostate Cancer 22Rv1 Cells. | Curr Pharm Biotechnol | 2024 | https://conductscience.org/library/papers/37605406 | PubMed |
| 19 | 33506324 | System Xc-: a key regulatory target of ferroptosis in cancer. | Invest New Drugs | 2021 | https://conductscience.org/library/papers/33506324 | PubMed |
| 20 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42980842 | Proton pump inhibitors in prevention of cisplatin-induced nephrotoxicity: a systematic review. | Support Care Cancer | 2026 | https://conductscience.org/library/papers/42980842 | PubMed |
| 42558470 | Beyond apoptosis: harnessing natural products to target alternative regulated cell death for overcoming multidrug resistance in cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42558470 | PubMed |
| 42501207 | Redox-regulated cell death in gastric cancer: Molecular insights and therapeutic opportunities. | J Physiol Biochem | 2026 | https://conductscience.org/library/papers/42501207 | PubMed |
| 42352028 | Targeting Cuproptosis and Ferroptosis via a ROS-Responsive Nanoplatform for Enhanced Synergistic Therapy Against Hepatocellular Carcinoma. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42352028 | PubMed |
| 42239904 | An emerging targeted strategy for gastric cancer: the multi-pathway regulatory potential of Chinese medicine monomers. | Front Oncol | 2026 | https://conductscience.org/library/papers/42239904 | PubMed |
| 42074066 | The Therapeutic Potential of Dihydroartemisinin in Cancer Treatment. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074066 | PubMed |
| 41897458 | The Role of Se-Containing Glutathione Peroxidases and Thioredoxin Reductases in Oncogenesis: Expression Paradoxes and Therapeutic Prospects. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/41897458 | PubMed |
| 41840422 | Anti-cancer mechanism of traditional Chinese medicine natural products targeting ferroptosis. | Chin Med | 2026 | https://conductscience.org/library/papers/41840422 | PubMed |
| 41833023 | The Role of Artemisinin and its Derivatives in Cancer Therapy via Ferroptosis: A Systematic Review of In Vitro, In Vivo, and In Silico Studies. | Anticancer Agents Med Chem | 2026 | https://conductscience.org/library/papers/41833023 | PubMed |
| 41809394 | Ferroptosis: A Double-Edged Sword in Cisplatin-Based Cancer Therapy and Acute Kidney Injury. | Cancer Manag Res | 2026 | https://conductscience.org/library/papers/41809394 | PubMed |
| 41750617 | Inducing Ferroptosis: Sensitization Strategy for Radiotherapy and Its Application. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/41750617 | PubMed |
| 41694363 | The dual roles of ferroptosis in digestive tract tumors: mechanisms, microenvironment regulation, and therapeutic integration with emphasis on immune interactions. | Front Immunol | 2026 | https://conductscience.org/library/papers/41694363 | PubMed |
| 41668813 | Pharmacological mechanisms of traditional Chinese medicine in treating gastric cancer: a focus on the ferroptosis regulation. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41668813 | PubMed |
| 41624874 | Global research landscape of ferroptosis in gastric cancer: a multidisciplinary bibliometric analysis based on multiple databases (2017-2025). | Front Immunol | 2025 | https://conductscience.org/library/papers/41624874 | PubMed |
| 41201056 | Targeting ferroptosis in Helicobacter pylori‑associated gastric cancer development: From molecular mechanisms to application prospects (Review). | Int J Oncol | 2026 | https://conductscience.org/library/papers/41201056 | PubMed |
| 41188993 | The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis. | Hereditas | 2025 | https://conductscience.org/library/papers/41188993 | PubMed |
| 40756346 | Artemisiae Annuae Herba: from anti-malarial legacy to emerging anti-cancer potential. | Theranostics | 2025 | https://conductscience.org/library/papers/40756346 | PubMed |
| 40462094 | Reprogrammed immuno-metabolic environment of cancer: the driving force of ferroptosis resistance. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40462094 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GPX4 | 2879 | PubTator's text mining | https://conductscience.org/library/genes/2879 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39733394
GET https://conductscience.org/api/papers/v1/39733394/references?page=2